Abelacimab, formerly known as MAA868, represents a promising approach to treating thrombosis. This antiplatelet agent is a selective monoclonal immunoglobulin that inhibits the integrin αIIbβ3, a critical player in https://www.targetmol.com/compound/abelacimab